The SGLT2i Treatment Gap in UK Primary Care: A Cross‐Sectional RWE Study of Prescribing in Clinical Practice
Authors' conclusion
SGLT2i therapy is significantly underutilised in UK primary care, particularly for CKD.
Study context
- Population
- Adults aged ≥18 years in UK primary care on 1 July 2024 with T2D, chronic kidney disease (CKD) and/or chronic HF eligible for SGLT2i (NICE clinical guidelines)
- Participants
- 9.8 million adults
- Outcome
- Current SGLT2i treatment (any SGLT2i prescription in the previous 2 months) among SGLT2i-eligible individuals
- Follow-up
- 1 July 2024
Methodological detailsroutinely collected electronic health records, Optimum Patient Care Research Database
- Routinely collected electronic health records
- Optimum Patient Care Research Database
Main finding
As reported in the abstract
Current SGLT2i treatment among eligible
All SGLT2i-eligible individuals currently prescribed an SGLT2i
17.5%
CKD-only patients treated among eligible (lowest)
3.8%
Meeting eligibility criteria for all three indications, treated (highest)
32.9%
Observational data: associations, not effects.
Further findings
Disease prevalence
- T2D
- 6.52%
- Diagnosed CKD
- 4.95%
- CKD including indicative CKD (sensitivity analysis)
- 6.07%
- Chronic HF
- 1.40%
Original publication
The SGLT2i Treatment Gap in UK Primary Care: A Cross‐Sectional RWE Study of Prescribing in Clinical Practice. Diabetes Obes Metab. Published 10 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →